Lung Cancer Europe (LuCE)

www.lungcancereurope.eu

 

Videos
16:37

Lung Cancer Europe (LuCE)

ASCO 2022 Early Stage NSCLC Updates

FEATURING Jarushka Naidoo
  • 316 views
  • July 26, 2022
  • 3
12:41

Lung Cancer Europe (LuCE)

Unresectable Stage III NSCLC: Key Findings

FEATURING Jarushka Naidoo
  • 288 views
  • July 26, 2022
  • 1
21:39

Lung Cancer Europe (LuCE)

Updates on Biomarker Testing and Oncogene-Driven NSCLC

FEATURING Enriqueta Felip
  • 275 views
  • February 23, 2022
  • 1
09:29

Lung Cancer Europe (LuCE)

Early Stage NSCLC: Standard Adjuvant & New Neoadjuvant Approaches, Evolution of Treatment & Staging

FEATURING Simon Ekman
  • 276 views
  • May 24, 2021
  • 2
07:07

Lung Cancer Europe (LuCE)

Treatment Approaches in Early Stage and Locally Advanced NSCLC: Impact of Emerging Targeted Agents, SBRT, and IO

FEATURING Simon Ekman
  • 159 views
  • May 24, 2021
09:30

Lung Cancer Europe (LuCE)

Metastatic EGFRm NSCLC: Navigating Treatment Options & Overcoming Resistance

FEATURING Simon Ekman
  • 229 views
  • May 24, 2021
04:44

Lung Cancer Europe (LuCE)

Considering Targeted Therapy Data for mNSCLC With ALK & KRAS Mutations

FEATURING Simon Ekman
  • 19 views
  • May 24, 2021
10:22

Lung Cancer Europe (LuCE)

IO in mNSCLC: Overview of Efficacy Data for Mono and Chemo Combinations, Resistance Strategies, and Advancements in Screening

FEATURING Simon Ekman
  • 188 views
  • May 24, 2021
08:15

Lung Cancer Europe (LuCE)

Liquid Biopsy in NSCLC: Potential of Targeted Therapy, CPIs, Biomarker Development, 5 yr OS With Pembro, Oncogenic Driver Negative Disease, Early Stage Disease

FEATURING Rolf A. Stahel
  • 313 views
  • December 22, 2020
  • 1
06:15

Lung Cancer Europe (LuCE)

Precision Oncology in Metastatic NSCLC: Efficacy Analysis of ALK, ROS1, BRAF V600, HER2, RET, NTRK, and G12C KRAS Targeting Drugs

FEATURING Rolf A. Stahel
  • 254 views
  • December 22, 2020
14:14

Lung Cancer Europe (LuCE)

Stage 4 NSCLC Molecular Testing: Histology for Treatment Allocation, Prognostic and Predictive Biomarkers, Testing Recommendations, Molecular Profiling, NGS

FEATURING Rolf A. Stahel
  • 101 views
  • December 22, 2020
09:34

Lung Cancer Europe (LuCE)

EGFR Mutations in mNSCLC: 1L TKI Inhibitors, Molecular Resistance Mechanism and Implication for Next Line Therapy, Role of ctDNA, EGFRi Efficacy

FEATURING Rolf A. Stahel
  • 268 views
  • January 21, 2021
07:27

Lung Cancer Europe (LuCE)

2020 ESMO Update Advanced ALK+ NSCLC: Should We Consider Lorlatinib a New 1L Option?

FEATURING Sanjay Popat
  • 242 views
  • November 26, 2020
  • 1
09:00

Lung Cancer Europe (LuCE)

2020 ESMO Update on Advanced EGFR-Mutated NSCLC: Mobocertinib (TAK-788), HER3-Directed ADC Patritumab Deruxtecan, EGFR-MET Bispecific Antibody Amivantamab + Lazertinib (3rd Gen TKI)

FEATURING Sanjay Popat
  • 356 views
  • November 26, 2020
  • 4
07:21

Lung Cancer Europe (LuCE)

2020 ESMO Update on IO in Advanced NSCLC: Is Atezo + Bev a Potential Option for non-Sq Disease w/ High PD-L1 Expression? Is There a Meaningful 5-Year OS Improvement With Pembro?

FEATURING Sanjay Popat
  • 95 views
  • November 26, 2020
08:05

Lung Cancer Europe (LuCE)

2020 ESMO Update on Operable NSCLC: Is There a Potential Benefit for Osimertinib After Surgery? Does Planned Thoracic RT Improve DFS in Completely Resected PN2 Disease?

FEATURING Sanjay Popat
  • 24 views
  • November 26, 2020
05:56

Lung Cancer Europe (LuCE)

2020 ESMO Update on Operable NSCLC: Are Neoadjuvant Atezolizumab or Durvalumab Safe?

FEATURING Sanjay Popat
  • 80 views
  • November 26, 2020
19:23

Lung Cancer Europe (LuCE)

2020 ESMO Q&A on Lung Cancer: Lorlatinib in Advanced Disease, Importance of Biomarkers in Drug Development, Role of Chemotherapy, Improvements in SCLC

FEATURING Sanjay Popat
  • 95 views
  • November 26, 2020